SCHEMBL114732

SCHEMBL114732

OC[C@H]1CCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL110675 1.00
SCHEMBL102835 1.00
Hydrochloric Acid SCHEMBL2146196 0.97
Hydrochloric Acid SCHEMBL2146329 0.97
Hydrochloric Acid SCHEMBL2146190 0.97
Bicarbonate SCHEMBL16500273 0.91 SLC6A1 (0.63)
SCHEMBL6467638 0.89 SLC6A1 (0.45)
SCHEMBL28988 0.85
SCHEMBL3303200 0.84
SCHEMBL213201 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 608 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111925848-B Efficient carbonyl sulfide removal solvent and preparation method thereof 中国石油集团工程股份有限公司 2021-10-15 CN claimed
CN-111925848-A Efficient carbonyl sulfide removal solvent and preparation method thereof 中国石油集团工程股份有限公司 2020-11-13 CN claimed
EP-4073062-B1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) RYVU THERAPEUTICS S A (PL) 2026-04-29 EP disclosed
US-12600732-B2 Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway NURIX THERAPEUTICS, INC. (US) 2026-04-14 US disclosed
US-12583862-B2 Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway NURIX THERAPEUTICS, INC. (US) 2026-03-24 US disclosed
EP-3565808-B1 COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS ARDELYX INC (US) 2026-03-04 EP disclosed
EP-4688772-A1 BIARYL DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-02-11 EP disclosed
US-20260035378-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS INC (US) 2026-02-05 US disclosed
EP-4680601-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES Sanofi (FR) 2026-01-21 EP disclosed
US-12528814-B2 Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof NURIX THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2026-01-15 US disclosed
US-5723444-A ENZYME INHIBITORS AND ANTICOAGULANTS ASTRA AB (SE) 1998-03-03 US disclosed
US-5602253-A STARTING MATERIAL FOR SERINE PROTEASE INHIBITORS AKTIEBOLAGET ASTRA (SE) 1997-02-11 US disclosed
US-5599816-A BACTERICIDE ABBOTT LABORATORIES (US) 1997-02-04 US disclosed
WO-1996039407-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1996-12-12 WO disclosed
CN-1127509-A Novel peptide derivatives ASTRA AB (SE) 1996-07-24 CN disclosed
EP-0701568-A1 NEW PEPTIDE DERIVATIVES Astra Aktiebolag (SE) 1996-03-20 EP disclosed
WO-1994029336-A1 NEW PEPTIDE DERIVATIVES ASTRA AKTIEBOLAG (SE) 1994-12-22 WO disclosed
CN-1016871-B Process for the preparation of bicyclic and tricyclic pyridine derivatives HOFFMANN LA ROCHE 7 CO F (CN) 1992-06-03 CN disclosed
CN-85108120-A The preparation of tricyclic pyridine derivative and application thereof 1986-11-05 CN disclosed